Swissmedic

Summary report on authorisation – Livmarli®

Swissmedic authorised Livmarli® (odevixibat) oral solution for cholestatic pruritus in PFIC patients aged 12 months and older.

Low obligation Product class Pharmaceuticals Switzerland Pharmaceuticals

Oral solution for the treatment of cholestatic pruritus (itching) in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC)

Read the official source ↗

Published by Swissmedic. HealthSignal links to the original document; the summary above is extracted from the source text.